Exact Sciences (EXAS) to Sell $869 Million of Common Stock in Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UBS Downgrades Exact Sciences (EXAS) to Neutral
October 29, 2020 6:11 AM EDTUBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from $125.00).
The analyst comments "We like the Thrive Deal on many levels, though timelines are lengthy & visibility limited. With COVID-19 pressuring the base business, plus... More
Exact Sciences (EXAS) to Acquire Thrive Earlier Detection for Cash and Stock up to $2.15 Billion
October 27, 2020 7:01 AM EDTExact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. The transaction was unanimously approved by both companies' Boards of Directors and is anticipated to close during the first quarter of 2021, subject to regulatory approval and the satisfaction of other conditions.
Combining Thrive's pioneering early-stage screening test, CancerSEEK, with Exact Sciences' best-in-class scientific platform, clinical... More
